Asthma Therapeutics in Major Developed Markets to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations
GBI Research, a leading business intelligence provider, has released its latest research report,""Asthma Therapeutics in Major Developed Markets to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations"".The asthma therapeutics market is forecast to grow marginally over the forecast period across the top eight developed nations, from $18.4 billion in 2013 to a projected value of $21.7 billion by 2020 at a Compound Annual Growth Rate (CAGR) of 2.4%. This is in spite of generic erosion facing several of the leading asthma brands, such as Advair (fluticasone propionate/salmeterol xinafoate), Symbicort (budesonide/formoterol fumarate) and Xolair (omalizumab), and is a consequence of new market entrants and rising disease prevalence.
The global prevalence of asthma is significant, believed to affect approximately 300 million people worldwide. This burden is predicted to increase in future, reaching 400 million by 2025.
Although the majority of asthma patients are able to manage their symptoms effectively using currently marketed products, some remain inadequately controlled with these same products. This unmet need, coupled with rising global prevalence, has resulted in strong industry interest.
Consequently, the current asthma pipeline is highly innovative, featuring several promising molecules in late-stage drug development. Biologics and monoclonal antibodies, the latter in particular, are gaining prominence within the indication. Novel monoclonal antibodies such as mepolizumab, reslizumab, lebrikizumab, and dupilumab target Interleukins (IL), or IL receptors, and have demonstrated potential in severe and inadequately controlled eosinophilic asthma, in turn representing a shift towards personalized therapy. Despite the fact that they target only a small patient sub-set, they are likely to be priced highly and to drive market growth, offsetting the impact of generic erosion.
The report covers and includes -
US Asthma Treatment Market Value to Hit $14 Billion by 2020, says GBI Research
The US treatment market for asthma will rise in value from $11.7 billion in 2013 to an estimated $14 billion by 2020, representing a Compound Annual Growth Rate (CAGR) of 2.6%, says business intelligence provider GBI Research.
The company’s latest report* states that the US is the single biggest asthma treatment market globally, reflecting the country’s large population size, high disease prevalence and the inflated cost of therapeutics in comparison with other major markets.
However, according to Fiona Chisholm, Associate Analyst for GBI Research, the asthma therapeutics market will be strongly characterized by generic erosion that will impact several of the leading brands over the forecast period, including Singulair (montelukast sodium), Advair (fluticasone propionate/salmeterol xinafoate), and Symbicort (budesonide/formoterol fumarate).
Chisholm explains: “Singulair’s patent expired in 2012, with the US Food and Drug Administration subsequently granting approval to several manufacturers, including Teva, Sandoz and Mylan, to market generic versions of the drug. As a consequence, sales revenue for Singulair has declined substantially in recent years.
“Advair and Symbicort have also recently lost patent protection in the US. However, substantial generic erosion has not occurred, due to regulatory hurdles and the difficulties inherent in trying to produce a bioequivalent Inhaled Corticosteroid/Long-Acting Beta Agonist (ICS/LABA) combination drug and inhaler device.”
While patent expirations are set to limit market growth to 2020, the impact of this will be offset by the uptake of recently approved and promising pipeline drugs.
Chisholm continues: “Arnuity, the follow-on product to the current ICS market leader Flovent, was approved in the US in August 2014, while Relvar, the follow-on product to the current ICS/LABA market leader Advair, is at the pre-registration phase. GBI Research believes both drugs will help to maintain sales revenue for their respective classes.
“Furthermore, the potential approval of several premium-priced, novel IL-targeting monoclonal antibodies, although limited by their target populations, will also contribute to growth.”
The analyst adds that the development of these IL-targeting therapies, as well as other novel drugs, also gives rise to potential phenotype-targeted treatment, which could be particularly useful for patients with severe asthma.
“If approved, these drugs will represent a significant step forward in asthma therapeutics, helping to achieve personalized treatment tailored to each individual patient,” Chisholm concludes.
*Asthma Therapeutics in Major Developed Markets to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations
This report provides analysis of the current marketed and pipeline products landscape for asthma treatment, including annualized market data from 2013 and forecast to 2020 across eight major markets, namely the US, France, Spain, Germany, Italy, UK, Japan and Canada.
This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook